Comparative efficacy of biosimilar denosumab and reference denosumab in treatment of postmenopausal osteoporosis: a systematic review and meta-analysis
Authors' conclusion
Biosimilar denosumab demonstrates comparable efficacy, safety and immunogenicity to reference denosumab.
Study context
- Population
- Postmenopausal women diagnosed with osteoporosis aged ≥ 45 years
- Participants
- 2,251 women7 randomized control trials (RCTs)
- Comparison
- Reference denosumab vs biosimilar denosumab
- Outcome
- LS BMD
Methodological detailsPRISMA, random effects model
- PRISMA
- Random effects model
Pooled result
As reported in the abstract
MD
0.02
95% CI −0.30 to 0.34
P = 0.92
Between Reference denosumab and Biosimilar denosumab
MD 0.02 (95% CI −0.30 to 0.34); P = 0.92
Further pooled results
| Outcome | MD (95% CI) | P value | |
|---|---|---|---|
| Total hip BMDSignificantly improved with reference denosumab | 0.24 (0.01–0.47) | P = 0.04 | |
| −0.200.20.40.6Difference (linear scale) |
Bone turnover markers
- No significant differences
Safety
Fractures, TAEs and ADA positivity
- No significant differences
Original publication
Comparative efficacy of biosimilar denosumab and reference denosumab in treatment of postmenopausal osteoporosis: a systematic review and meta-analysis. Osteoporos Int. Published 29 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →